Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Immunocore Holdings plcNASDAQ: IMCR

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $434K fell 47.8% year over year, behind the +39.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 83.4% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.

Context

  • Cost of revenue amounted to 2.1% of revenue in FY2025, down 0.1 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -47.8% toward the trailing-twelve-month pace of +39.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$434K-83.4% QoQ
Last fiscal yearDec 2025
$6.21M+12.1% YoY
LTMMar 2026
$4.61M+39.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.8%——
1 year+12.1%——
3-year CAGR+5.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

Mixed currencies · from the income statement

Latest · FY2025
6.21M USD
Year-over-year change
+12.1%

Cost of Revenue vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.0% is the 3rd highest of 10, against a peer median of -6.4%.
  • Cost of revenue amounts to 1.2% of revenue for IMCR, versus a peer median of 20.6%.
IMCR Competitors
Cost of Revenue for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€771.34M EUR+32.4%-41.0%29.2%
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+209.9%1217.6%
XNCRXencor, Inc.LTM Jun 2026$59.51M USD-6.4%-62.5%56.7%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
JANXJanux Therapeutics, Inc.LTM Mar 2026$9.91M USD-79.7%+34.1%45.9%
CGENCompugen Ltd.LTM Mar 2026$8.68M USD+5.4%+111.7%11.9%
RCUSArcus Biosciences, Inc.LTM Jun 2026$7M USD——6.0%
IBRXImmunityBio, Inc.LTM Sep 2026$6.07M USD+40.5%—3.3%
IMCRImmunocore Holdings plcLTM Mar 2026$4.61M USD+39.0%+5.5%1.2%
IMTXImmatics N.V.LTM Mar 2026€0 EUR-100.0%—0.0%
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding IMCR) —-6.4%+57.1%20.6%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.